Latest Articles

Latest Videos

Video List based on Category on Node Page

Latest Videos

Dr Shaji Kumar reviews the rationale for targeting the BCL-2 protein in multiple myeloma (MM) and the results of the recent phase I study of venetoclax. He also discusses selinexor combination therapy and the role of minimal residual disease in assessing response to therapies. FILMED AT THE AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING 2016, SAN DIEGO, CALIFORNIA, US Dr Shaji Kumar has...
Dr Mohamad Mohty discusses consolidation and maintenance therapy in multiple myeloma and whether these therapies can replace autologous stem cell transplantation (ASCT). FILMED AT THE AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING 2016, SAN DIEGO, CALIFORNIA, US
Andrew Spencer discusses the role ofhistone deacetylase (HDAC) inhibition in multiple myeloma and what we need to understand better to explore the further potential of HDAC inhibition. FILMED AT THE EUROPEAN HEMATOLOGY ASSOCIATION (EHA) ANNUAL MEETING, JUNE 2016 WHY IS HISTONE DEACETYLASE (HDAC) INHIBITION IMPORTANT IN MULTIPLE MYELOMA (MM)? 00:12 – I think HDAC inhibition is...